What AbCellera’s upcoming ABCL635 Phase 1 data could reveal about the future of menopause treatment
AbCellera will reveal Phase 1 ABCL635 data on May 11. Read why this menopause drug update could matter for investors and women’s health watchers.
Pharma & Biotech
Pharma & Biotech
Can ABCL635 redefine non-hormonal menopause treatment? Inside AbCellera’s Phase 2 push
AbCellera advances ABCL635 into Phase 2 for hot flashes. Find out what this means for non-hormonal menopause care and the biotech’s GPCR strategy.